Pacira Biosciences Inc. (PCRX)

43.33
NASDAQ : Health Technology
Prev Close 43.33
Day Low/High 43.26 / 44.03
52 Wk Low/High 30.00 / 55.00
Avg Volume 615.90K
Exchange NASDAQ
Shares Outstanding 41.30M
Market Cap 1.79B
P/E Ratio 240.72
Div & Yield N.A. (N.A)
New Lifetime High Reached: Pacira Pharmaceuticals (PCRX)

New Lifetime High Reached: Pacira Pharmaceuticals (PCRX)

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a new lifetime high candidate

Pacira Pharmaceuticals, Inc. Reports 2013 Financial Results: Fourth Quarter EXPAREL Revenues Increase 53 Percent Over Third Quarter

Pacira Pharmaceuticals, Inc. Reports 2013 Financial Results: Fourth Quarter EXPAREL Revenues Increase 53 Percent Over Third Quarter

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on the commercial success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and...

Pacira Pharmaceuticals, Inc. Announces Timing For 2013 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. Announces Timing For 2013 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s fourth quarter and year ended December 31, 2013, will be released before the market opens on Tuesday, February...

Pacira Pharmaceuticals (PCRX) Hits New Lifetime High Today

Pacira Pharmaceuticals (PCRX) Hits New Lifetime High Today

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a new lifetime high candidate

Data Update Supports Infiltration With EXPAREL® Into The Transversus Abdominis Plane For Postsurgical Pain Management

Data Update Supports Infiltration With EXPAREL® Into The Transversus Abdominis Plane For Postsurgical Pain Management

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced key findings supporting the use of EXPAREL® (bupivacaine liposome injectable suspension) infiltrated into the transversus abdominis plane (or...

Pacira Pharmaceuticals (PCRX) Reaches New Lifetime High Today

Pacira Pharmaceuticals (PCRX) Reaches New Lifetime High Today

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a new lifetime high candidate

Phase 4 IMPROVE Publication Finds EXPAREL®- Based Multimodal Analgesia Reduces Opioid Use, Adverse Events And Hospital Stay Following Laparoscopic Surgery

Phase 4 IMPROVE Publication Finds EXPAREL®- Based Multimodal Analgesia Reduces Opioid Use, Adverse Events And Hospital Stay Following Laparoscopic Surgery

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from the IMPROVE study in laparoscopic colectomy.

First Week of August 2014 Options Trading For Pacira Pharmaceuticals (PCRX)

First Week of August 2014 Options Trading For Pacira Pharmaceuticals (PCRX)

Investors in Pacira Pharmaceuticals Inc. saw new options begin trading this week, for the August 2014 expiration.

4 Stocks Spiking on Big Volume

4 Stocks Spiking on Big Volume

Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Watch Out: Barbarians At The Gate For Pacira Pharmaceuticals (PCRX)

Watch Out: Barbarians At The Gate For Pacira Pharmaceuticals (PCRX)

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Pacira Pharmaceuticals, Inc. Announces Submission Of Prior Approval Supplement For Additional EXPAREL® Manufacturing Suite

Pacira Pharmaceuticals, Inc. Announces Submission Of Prior Approval Supplement For Additional EXPAREL® Manufacturing Suite

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it has submitted a Prior Approval Supplement (PAS) with the U.

Pacira Pharmaceuticals, Inc. To Present At The 25th Annual Piper Jaffray Healthcare Conference

Pacira Pharmaceuticals, Inc. To Present At The 25th Annual Piper Jaffray Healthcare Conference

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 25 th Annual Piper Jaffray...

First Week Of January 2014 Options Trading For Pacira Pharmaceuticals (PCRX)

First Week Of January 2014 Options Trading For Pacira Pharmaceuticals (PCRX)

Investors in Pacira Pharmaceuticals Inc. saw new options begin trading this week, for the January 2014 expiration.

Pacira Pharmaceuticals, Inc. To Present At November Investor Conferences

Pacira Pharmaceuticals, Inc. To Present At November Investor Conferences

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present an overview of the company at ...

Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL® Revenue Of $20.0 Million And Full Third Quarter 2013 Financial Results

Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL® Revenue Of $20.0 Million And Full Third Quarter 2013 Financial Results

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on the commercial success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and...

Pacira Pharmaceuticals, Inc. Announces Timing For Third Quarter 2013 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. Announces Timing For Third Quarter 2013 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s third quarter ended September 30, 2013, will be released before the market opens on Thursday, October 31, 2013.

Pacira Pharmaceuticals, Inc. Announces Partnership To Support Uptake Of EXPAREL® Among The Orthopedic Marketplace

Pacira Pharmaceuticals, Inc. Announces Partnership To Support Uptake Of EXPAREL® Among The Orthopedic Marketplace

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the initiation of a five-year promotion arrangement with CrossLink Bioscience, LLC, an orthopedic device distributor based in Atlanta.

Trade-Ideas: Pacira Pharmaceuticals (PCRX) Is Today's New Lifetime High Stock

Trade-Ideas: Pacira Pharmaceuticals (PCRX) Is Today's New Lifetime High Stock

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a new lifetime high candidate

Study Shows EXPAREL® Provided Improved Pain Control, Shorter Length Of Hospital Stay And Substantial Cost Savings Following Total Knee Replacement

Study Shows EXPAREL® Provided Improved Pain Control, Shorter Length Of Hospital Stay And Substantial Cost Savings Following Total Knee Replacement

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced results from a 200-patient study evaluating the benefits of EXPAREL ® (bupivacaine liposome injectable suspension) as the foundation of a ...

Insider Trading Alert - Armstrong World Industries And 4 Others Traded By Insiders

Insider Trading Alert - Armstrong World Industries And 4 Others Traded By Insiders

Stocks with insider trader activity include AWI, BSFT, GEO, PCRX and CTSH

Pacira Pharmaceuticals, Inc. Announces Appointment Of Life Sciences Industry Veterans Mark Kronenfeld, M.D., And Dennis Winger To Its Board Of Directors

Pacira Pharmaceuticals, Inc. Announces Appointment Of Life Sciences Industry Veterans Mark Kronenfeld, M.D., And Dennis Winger To Its Board Of Directors

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Mark A.

Pacira Pharmaceuticals, Inc. Reports Second Quarter EXPAREL® Revenue Of $15.2 Million And Full Second Quarter 2013 Financial Results

Pacira Pharmaceuticals, Inc. Reports Second Quarter EXPAREL® Revenue Of $15.2 Million And Full Second Quarter 2013 Financial Results

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on the commercial success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and...

Pacira Pharmaceuticals, Inc. To Present At The Wedbush 2013 Life Sciences Management Access Conference

Pacira Pharmaceuticals, Inc. To Present At The Wedbush 2013 Life Sciences Management Access Conference

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Wedbush 2013 Life Sciences...

EXPAREL Phase 3 Clinical Trial In Intercostal Nerve Block Does Not Meet Primary Endpoint

EXPAREL Phase 3 Clinical Trial In Intercostal Nerve Block Does Not Meet Primary Endpoint

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from its second pivotal, Phase 3 clinical trial assessing the safety and efficacy of EXPAREL ® (bupivacaine liposome injectable ...

New Study Shows Significant Reduction In Opioids, Length Of Hospital Stay And Cost Of Care For Patients Receiving EXPAREL® As The Foundation Of A Multimodal Postsurgical Pain Regimen

New Study Shows Significant Reduction In Opioids, Length Of Hospital Stay And Cost Of Care For Patients Receiving EXPAREL® As The Foundation Of A Multimodal Postsurgical Pain Regimen

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that results from the second IMPROVE study to complete its prospective Phase 4 clinical program were published in the online version of the Journal ...

Insider Trading Alert - Vertex Pharmaceuticals And 4 Others Traded By Insiders

Insider Trading Alert - Vertex Pharmaceuticals And 4 Others Traded By Insiders

Stocks with insider trader activity include VRTX, CVLT, PCRX, PG and GPK

Top Insider Trades: CHK ZINC PCRX SNTA

Top Insider Trades: CHK ZINC PCRX SNTA

The top 10 open-market insider purchases and sales filed at the SEC Tuesday.

Commit To Buy Pacira Pharmaceuticals At $22.50, Earn 11.7% Annualized

Commit To Buy Pacira Pharmaceuticals At $22.50, Earn 11.7% Annualized

Investors eyeing a purchase of Pacira Pharmaceuticals Inc. shares, but cautious about paying the going market price of $28.66/share, might benefit from considering selling puts among the alternative strategies at their disposal.

5 Buy Signals From the Health Care Sector

5 Buy Signals From the Health Care Sector

The health care sector is strong right now -- and that's creating some tradable opportunities for investors.

Don't Grab the Falling Knife

Algorithmic trading routines are showing absolutely no inclination to ease up on aggressive sell strategies.

TheStreet Quant Rating: C (Hold)